CLAIMS:

1. A liquid pharmaceutical composition comprising:
   (a) tocilizumab antibody;
   (b) a histidine buffer;
   (c) a stabilizer selected from lactic acid or salts thereof;
   (d) a free amino acid selected from arginine or glycine;
   (e) a polysorbate;
   (f) water for injection; and
   (g) optionally a salt;

wherein the composition has a pH between 5.5 and 7.0.

2. The liquid pharmaceutical according to claim 1, wherein the composition has a pH between 5.8 and 6.2.

3. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the stabilizer is lactic acid or sodium lactate.

4. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the free amino acid is arginine.

5. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the polysorbate is polysorbate 80.

6. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the optional salt is sodium chloride.

7. The liquid pharmaceutical composition according to any one of the preceding claims, wherein the composition comprises:

- 15 to 200 mg/ml of tocilizumab antibody;
- 10 to 25 mM histidine;
- 5 to 15 mM sodium lactate or lactic acid;
- 50 to 150 mM arginine
- 0.1 to 0.2 mM polysorbate 80
- water for injection; and
- optionally 5 to 50 mM sodium chloride.

8. The liquid pharmaceutical composition according to any one of claims 1 to 6, wherein the composition comprises:

- 15 to 200 mg/ml of tocilizumab antibody;
- 10 to 25 mM histidine;
- 5 to 15 mM sodium lactate or lactic acid;
- 50 to 150 mM arginine
- 0.1 to 0.2 mM polysorbate 80
- water for injection; and
- 5 to 50 mM sodium chloride.

9. A method of manufacturing the liquid pharmaceutical composition of any one of claims 1 to 6, comprising mixing together the tocilizumab, the histidine buffer, the stabilizer, the free amino acid, the polysorbate, and optionally the salt.

10. A method of manufacturing the liquid pharmaceutical composition of claim 7 or claim 8, comprising mixing together the tocilizumab, the histidine, the sodium lactate or lactic acid, the arginine, the polysorbate 80, and optionally the salt.

11. A kit comprising: (i) the liquid pharmaceutical composition of any one of claims 1 to 8, and (ii) a drug delivery device selected from a vial, ampoule, syringe, injection pen, or intravenous bag; wherein the liquid pharmaceutical composition is optionally contained in a separate package or container from the drug delivery device;

optionally wherein the kit further comprises a set of instructions regarding the administration of the liquid pharmaceutical composition.

12. A drug delivery device selected from a vial, ampoule, syringe, injection pen, or intravenous bag, comprising a liquid pharmaceutical composition as claimed in any one of claims 1 to 8.

13. A method of manufacturing the drug delivery device of claim 12, comprising incorporating the liquid pharmaceutical composition of any one of claims 1 to 8 within a drug delivery device selected from a vial, ampoule, syringe, injection pen, or intravenous bag.

14. A liquid pharmaceutical composition as claimed in any of claims 1 to 8 for use as a medicament.

15. A liquid pharmaceutical composition as claimed in any of claims 1 to 8 for use in the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, Giant cell arteritis or systemic sclerosis.